The Diabetes separation has moved from announcement to operating reality, and that reordering is the single most consequential event of the third quarter. Management's quarterly report describes a new independent entity called MiniMed Group taking shape on an eighteen-month horizon, a January credit facility that pre-funds the carve-out, and a December plan to terminate a third-party manufacturing agreement inside the Diabetes operating unit. None of that shows up as a clean number on the income statement, but every one of those actions changes the shape of the consolidated business the analyst is being asked to value. At a recent price near $92, MDT trades with a market capitalization just under $118B and a dividend yield above three percent. The equity sits roughly mid-range in its fifty-two week band between $73 and $106, and a forward earnings multiple near fourteen times frames the shares as a defensive large-cap medical-device franchise rather than a high-growth disruptor.
The third-quarter revenue line itself reinforces the franchise framing. Consolidated net sales of $9.0B advanced nine percent year-over-year on a reported basis, with the Cardiovascular Portfolio doing the heaviest lifting. Cardiac Rhythm and Heart Failure sales grew twenty percent in the quarter, paced by Micra leadless pacemakers, the Aurora extravascular implantable cardioverter defibrillator, and continued strength in the PulseSelect pulsed field ablation portfolio. Neuroscience grew four percent, Medical Surgical five percent, and Diabetes fifteen percent, the latter driven by international adoption of the MiniMed 780G automated insulin delivery system. GAAP diluted earnings per share of $0.89 declined twelve percent year-over-year, while non-GAAP diluted earnings per share of $1.36 fell two percent, with the gap explained by elevated restructuring, certain litigation, and accelerated intangible amortization charges. The pattern of high single-digit revenue growth, low single-digit non-GAAP earnings growth, and a portfolio simplification that is still in motion is the central tension for the equity.
The strongest counter-argument to a constructive view is that operating leverage is missing in the print. Cost of products sold rose faster than revenue in percentage terms, weighed down by roughly $90M of incremental tariff duties in the quarter, $84M of asset write-offs, and an unfavorable currency effect, while selling, general, and administrative spend stepped up to support the Diabetes separation and the new-product launches. Free cash flow generation of $3.3B over the nine-month period is healthy, but the medical-device-excise-tax backdrop, the pending International Emergency Economic Powers Act tariff decision, and the still-unresolved timeline on the Diabetes spin all argue for patience. The case for the equity rests on whether Cardiovascular and Diabetes can each deliver double-digit growth as the spin approaches and whether the Hugo robotic-assisted surgery platform, the Symplicity Spyral renal denervation franchise, and the Affera pulsed field ablation mapping system can layer on top. Those three product cycles are the forward variables that decide whether the multiple expands from here or compresses.